OraSure Technologies, Inc. (NASDAQ:OSUR) CFO Kenneth J. Mcgrath Purchases 64,000 Shares of Stock

OraSure Technologies, Inc. (NASDAQ:OSUR) CFO Kenneth J. Mcgrath purchased 64,000 shares of the stock in a transaction dated Thursday, February 27th. The stock was acquired at an average price of $3.15 per share, for a total transaction of $201,600.00. Following the completion of the transaction, the chief financial officer now directly owns 371,013 shares of the company’s stock, valued at approximately $1,168,690.95. The trade was a 20.85 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

OraSure Technologies Trading Up 2.3 %

Shares of OSUR stock opened at $3.13 on Friday. The company has a market capitalization of $233.48 million, a price-to-earnings ratio of 20.87 and a beta of 0.05. The firm has a 50-day moving average price of $3.78 and a 200 day moving average price of $4.01. OraSure Technologies, Inc. has a twelve month low of $2.68 and a twelve month high of $8.04.

Hedge Funds Weigh In On OraSure Technologies

A number of institutional investors have recently modified their holdings of OSUR. BNP Paribas Financial Markets boosted its position in OraSure Technologies by 27.2% during the third quarter. BNP Paribas Financial Markets now owns 855,951 shares of the medical instruments supplier’s stock worth $3,655,000 after acquiring an additional 183,191 shares during the last quarter. Franklin Resources Inc. boosted its holdings in shares of OraSure Technologies by 28.5% during the third quarter. Franklin Resources Inc. now owns 269,269 shares of the medical instruments supplier’s stock worth $1,091,000 after purchasing an additional 59,723 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of OraSure Technologies by 5.8% in the third quarter. JPMorgan Chase & Co. now owns 847,933 shares of the medical instruments supplier’s stock valued at $3,621,000 after purchasing an additional 46,216 shares during the period. Barclays PLC increased its stake in OraSure Technologies by 182.6% in the third quarter. Barclays PLC now owns 195,793 shares of the medical instruments supplier’s stock valued at $836,000 after purchasing an additional 126,503 shares during the last quarter. Finally, Exchange Traded Concepts LLC purchased a new position in OraSure Technologies during the fourth quarter worth about $287,000. Institutional investors and hedge funds own 93.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com lowered OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Saturday, February 22nd.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.